View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 16, 2017

Actinogen begins enrolment in Phase II trial of Xanamem to treat Alzheimer’s disease

Australian-based biotech firm Actinogen Medical has begun patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer's disease.

Australian-based biotech firm Actinogen Medical has begun patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer’s disease.

Developed in collaboration with Edinburgh University in Scotland, Xanamem is designed to block the excess production of cortisol in the brain.

The initiation of patient enrolment follows the approval from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The double-blind, randomised, placebo-controlled Phase II trial will evaluate the safety, tolerability and efficacy of Xanamem over 12 weeks in patients with mild dementia.

"It is significant that the first XanADu patient worldwide has been enrolled in Australia and we can all be justifiably proud that Australia is leading the way in developing this promising new treatment for Alzheimer’s disease."

Actinogen Medical chief executive officer Dr Bill Ketelbey said: “It is significant that the first XanADu patient worldwide has been enrolled in Australia and we can all be justifiably proud that Australia is leading the way in developing this promising new treatment for Alzheimer’s disease.

“Given the growing number of people with Alzheimer’s and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer’s patients, and their carers and families worldwide.”

With the first patient recruited at the Central Coast Neurosciences Research site in New South Wales, Australia, the trial is expected to enrol a total of 174 patients across 20 clinical sites in the US, the UK and Australia.

The final patient is expected to be enrolled into the trial by the fourth quarter of next year and the top line results are estimated to be reported in the first quarter of 2019.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena